Efficacy of Sorafenib Combined with Interventional Therapy on Primary Liver Cancer Patients and Its Effect on Serum AFP, VEGF, and GGT

Table 1

Comparison of patients’ general information.

Group	Group A (n = 60)	Group B (n = 60)	X^2/t
Gender
Male	52	50	0.261	0.609
Female	8	10
Age (years)
Range	34–76	35–76
Mean age	46.32 ± 5.21	46.98 ± 5.25	0.691	0.491
Liver function class
A	48	47	0.051	0.822
B	12	13
Hepatitis type
Hepatitis C	10	12	0.223	0.637
Hepatitis B	50	48
Complication
Ascites	30	32	0.134	0.715
Portal vein tumor thrombus	10	9	0.063	0.803
Cirrhosis	42	40	0.154	0.695
TNM staging
II	24	25	0.035	0.853
III	26	25	0.034	0.853
IV	10	10	0.000	1.000
Clinical type
Diffused	10	12	0.223	0.637
Nodal	20	21	0.037	0.847
Massive	30	27	0.301	0.583
Maximum diameter of tumor (mm)
Range	50–140	48–142
Mean diameter	85.65 ± 20.65	86.98 ± 20.66	0.353	0.725
ECOG score
0 point	35	36	0.035	0.853
1 point	25	24
Educational degree
Senior high school and below	22	21	0.036	0.849
College and above	38	39

The physical health and therapy resistance of patients.